a0388z
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
18 May 2021 15:30 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 14 May 2021, Pascal
Soriot, Chief Executive Officer, was granted an award of the
Company's ordinary shares of $0.25 each (Ordinary Shares) under the
terms of the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
This award forms part of the AZPSP award granted to Mr Soriot on 5
March 2021. As described in AstraZeneca's 2020 Directors'
Remuneration Report, it has been made in accordance with the
Directors' Remuneration Policy and amended rules of the AZPSP
approved by shareholders at the Company's 2021 Annual General
Meeting.
PDMR
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
Pascal Soriot
|
19,391
|
£68.44
|
The award is subject to a combination of performance measures
focused on scientific, commercial, financial and ESG
performance. Further
details of the performance measures attached to the AZPSP award can
be found in AstraZeneca's 2020 Directors' Remuneration Report,
which is contained within the AstraZeneca Annual Report and Form
20-F Information 2020 (available on the Company's website at
www.astrazeneca.com/annualreport2020).
The performance measures will be assessed over a three-year
performance period (1 January 2021 to 31 December 2023). The
Ordinary Shares granted under the AZPSP are subject to a two-year
holding period following the performance period, and are due to
vest on the fifth anniversary of grant.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Pascal Soriot
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Executive Officer
|
b)
|
Initial notification /Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Grant of a share award under the AstraZeneca Performance Share
Plan
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
£68.44 |
19,391 |
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
14 May 2021
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries, and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
AstraZeneca contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
18 May 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|